Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05209152 · OUTCOME

Event-free Survival

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia · Source last updated 2025-07-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Cycle 1 to disease progression or end of study, whichever occurred earlier (cycle length = 28 days). Median time on study was 4.1 months

Analysis population: As pre-specified in Section 10 of the statistical analysis plan, EFS was not analyzed.

Groups in this outcome

Part 1A Dose Exploration: AMG 176 Dose Level 1

Participants received IV AMG 176 at dose level 1 once a week in 28-day cycles. Treatment was planned until disease progression or unacceptable toxicity.

Part 1A Dose Exploration: AMG 176 Dose Level 1 Then Dose Level 2

Participants received IV AMG 176 at dose level 1 on cycle 1 day 1 and then dose level 2 from cycle 1 day 8 and once a week thereafter (each cycle = 28 days). Treatment was planned until disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 1A Dose Exploration: AMG 176 Dose Level 10
Part 1A Dose Exploration: AMG 176 Dose Level 1 Then Dose Level 20

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
groups
  1. description
    Participants received IV AMG 176 at dose level 1 once a week in 28-day cycles. Treatment was planned until disease progression or unacceptable toxicity.
    id
    OG000
    title
    Part 1A Dose Exploration: AMG 176 Dose Level 1
  2. description
    Participants received IV AMG 176 at dose level 1 on cycle 1 day 1 and then dose level 2 from cycle 1 day 8 and once a week thereafter (each cycle = 28 days). Treatment was planned until disease progression or unacceptable toxicity.
    id
    OG001
    title
    Part 1A Dose Exploration: AMG 176 Dose Level 1 Then Dose Level 2
population Description
As pre-specified in Section 10 of the statistical analysis plan, EFS was not analyzed.
reporting Status
POSTED
time Frame
Cycle 1 to disease progression or end of study, whichever occurred earlier (cycle length = 28 days). Median time on study was 4.1 months
title
Event-free Survival
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice